Embodiments of the present invention generally relate to the field of methods and devices for nitric oxide delivery.
Nitric oxide (NO) is a gas that, when inhaled, acts to dilate blood vessels in the lungs, improving oxygenation of the blood and reducing pulmonary hypertension. Because of this, nitric oxide is provided as a therapeutic gas in the inspiratory breathing gases for patients with pulmonary hypertension.
Typically, inhaled NO is delivered in a carrier gas from a high pressure source (such as a pressurized cylinder) to the patient at or near ambient pressure by means of a respiratory tube for ICU ventilator bound or anesthesia patients or a nasal cannula for spontaneously breathing patients. It is particularly challenging to deliver an accurate and consistent dose to the patient through a nasal cannula as dilution of the dose can occur through retrograde flow and diffusion of other gases.
Delivery of NO may require transit through a nasal cannula. During patient inhalation and exhalation, a driving pressure gradient can cause retrograde flow in the nasal cannula supply lumen, thereby diluting the NO dose in the cannula with exhaled gas. In addition, diffusion of ambient gasses can occur through the cannula itself during the transit time of NO through the cannula. Oxygen is of specific concern as it reacts with NO to form nitrogen dioxide (NO2) thereby reducing the NO concentration. This is further exacerbated by the fact that patients on NO may also require oxygen therapy. Both of these issues can dilute the delivered dose of NO during inhaled NO therapy.
Accordingly, there is a need for new methods and apparatuses for preventing dilution of dosing within the delivery conduit of a nitric oxide delivery apparatus.
Aspects of the present invention relate to improved nasal cannulas that minimize retrograde flow and permeation of oxygen during NO therapy while allowing NO delivery to both nares of the nostril. Such cannulas may reduce dilution of the delivered dose by using cannula materials that limit oxygen diffusion through the cannula walls and/or utilize cannula configurations that prevent mixing of co-delivered O2 and NO and/or reduce retrograde diffusion through the patient end of the cannula. Aspects of the present invention also relate to methods of minimizing the dilution of the NO dose. Other aspects pertain to methods of treatment utilizing these nasal cannulas and/or methods of administration. Other aspects of the invention relate to methods of manufacturing multi-lumen cannulas and their nosepieces.
So that the manner in which the above recited features of the present invention can be understood in detail, a more particular description of the invention, briefly summarized above, may be had by reference to embodiments, some of which are illustrated in the appended drawing. It is to be noted, however, that the appended drawing illustrates only typical embodiments of this invention and are therefore not to be considered limiting of its scope, for the invention may admit to other equally effective embodiments.
Methods of delivering inhaled nitric oxide (NO) should ideally be optimized to ensure accurate and consistent delivery of the dose to the patient. Typically, NO is delivered at relatively low volumetric percent concentrations in a carrier gas. Nitrogen is a common carrier gas for NO delivery because nitrogen is non-reactive with NO, but other inert carrier gases such as helium may be used. Delivery of the NO/N2 gas mixture to the patient typically requires that the gas travel from a high pressure NO source (such as a pressurized cylinder) to the patient at or near ambient pressure by means of a respiratory tube for ICU ventilator bound or anesthesia patients or a nasal cannula for spontaneously breathing patients. This travel of the NO is ideally devoid of contact with other gasses, such as ambient air, oxygen, carbon dioxide, etc., until the gas enters the patient's upper respiratory tract. However, in practice, this is not easily achieved. Specifically, oxygen and ambient air can enter the delivery system at a number of points as follows:
The dilution of NO during pulsed NO therapy may be problematic because only a small volume of NO is delivered to the patient. For example, the NO-containing gas may be administered in pulses less than 1 mL. With small pulse volumes, even small volumes of retrograde flow or diffused gases may be significant because the NO dose may be diluted.
Materials:
One or more embodiments of the present invention relate to a nasal cannula that addresses one or more of these above sources of oxygen/NO contact and thereby dilution of the intended NO dose. One particular source of oxygen that may be minimized is the transit of oxygen across the cannula walls. In one or more embodiments, a cannula is provided that includes a smaller inside diameter (ID) delivery tube/lumen for NO. This smaller ID tube reduces the transit time of the NO molecules through the cannula, thereby reducing the time available for oxygen to diffuse across the walls of the cannula and oxidize the internal NO into NO2.
Another approach to minimize the oxygen contact provided by oxygen diffusion across the cannula walls is to use a wall material that minimizes the oxygen diffusion rate. Accordingly, in some embodiments, the cannula wall comprises a material with a low oxygen diffusion coefficient. Polyvinyl chloride (PVC) is currently a common material for constructing nasal cannulas, but it is not optimal for reducing oxygen diffusion through the cannula walls. Accordingly, some embodiments provide using urethane or another similar soft material. In some embodiments, the urethane or other soft material includes an additive to enhance the resistance to oxygen diffusion. Examples of suitable additives include oxygen resistant polymers such as polyvinylidene chloride (PVDC), ethylene vinyl alcohol (EVOH), polyamide (PA) or similar materials. Alternatively, PVC may be used as the cannula material, but one or more additives such as oxygen resistant polymers may be incorporated to reduce the oxygen diffusion coefficient of the material. The oxygen resistant polymers may be incorporated into the urethane or other cannula material through co-extrusion. Such an extrusion may be achieved with a dual head extruder.
Pneumatic Configurations:
Another potential source of nitric oxide dilution is from retrograde flow in the nasal cannula. Retrograde flow, also known as cross flow, is a phenomenon in which ambient air flows in opposite directions between the two delivery prongs of the nasal cannula. As shown in
Accordingly, aspects of the present invention also provide nasal cannulas that may minimize the retrograde flow in the nasal cannula. Such nasal cannulas may include a means of delivering oxygen and therapeutic gas containing NO, and may be able to transmit pressure transients associated with inhalation-based gas flow triggering. If the cannulas deliver oxygen in addition to NO, the oxygen may be provided by an oxygen conserver or an oxygen concentrator.
In one or more embodiments, the nasal cannula has two lumina (i.e. a dual-lumen cannula).
As shown in
Also, the geometry of the nasal cannula lumina may be optimized to prevent retrograde flow. Thus, in addition to circular or parabolic cross-sections, the cross-section of any of the nasal cannula lumina described herein may be square, rectangular, triangular or any other regular or irregular shape to minimize dose dilution. When one or more cross-sectional areas are not circular, then the ratio of inner diameters may be the square root of the ratio of the surface areas of the two lumina sections.
Alternatively, a dual-lumen cannula may have a first lumen for oxygen delivery and a second lumen for delivery of NO and transmitting the pressure signal for the trigger sensor. Such a two lumina configuration is shown in
The first lumen for carrying oxygen may be constructed with lumen inner diameter geometry consistent with industry norms. For instance, nasal cannulas with rated 6 LPM oxygen delivery capacity typically provide an oxygen lumen inner diameter of approximately 0.080″ at or near the nosepiece.
The second lumen of the dual-lumen cannula may have a geometry unique to the gas delivery objectives of the nitric oxide delivery system. Nitric oxide delivery systems which pulse nitric oxide gas into the patient are believed to have optimal clinical efficacy when a pulse or flow of nitric oxide is delivered to the patient as early in the inspiratory phase as possible. Therefore, any pneumatic delays would not be optimal. Further, the shape of the flow waveform as delivered by the nitric oxide delivery system is, optimally, not distorted during transit from the device to the patient. In addition, the transit of the pressure signal from the patient indicative of inspiratory effort preferably is not delayed/distorted when in transit from the patient back to the device. Finally, the volume of potential nitric oxide mixing with either exhaled gas or ambient gas is preferably minimized to reduce the potential for oxidation of nitric oxide at the nosepiece of the cannula, which again can produce NO2 which dilutes the NO dose and is a known respiratory irritant.
In order to achieve the goals described above for the second lumen, there are several competing metrics of lumen ID optimization as noted below:
Therefore, an optimal inner diameter dimension of the second lumen would address all of these concerns to ensure adequate device performance. Such optimal ID dimensions may vary depending on the volume of NO-containing gas delivered by the nitric oxide delivery device. For example, a nitric oxide delivery device may deliver pulses of NO-containing gas with a minimum dose volume of 0.35 mL. In order to ensure volumetric dosing accuracy, it is preferable that no more than 10% of the dose can be lost due to ambient bleed of NO in between inspiratory efforts. Such a bleed can occur during the exhalation phase in which imbalances in the flow out of the nostrils results in a “high flow nostril” and a “low flow nostril.” Flow into the prong from the high flow nostril may result in flow of out of (gas loss out of) the prong of the low flow nostril. This gas, which is located in the “U” shaped portion of the tee'd lumen, is lost to ambient during the exhalation phase and would consist of NO therapeutic gas. Therefore, one or more embodiments of the present invention limit the internal volume of this “U” shape to be no more than 10% of the minimum dose volume (i.e. 0.035 mL for a 0.35 mL pulse of therapeutic gas), thus ensuring acceptable NO loss to ambient during the exhalation phase. Such a requirement of 0.035 mL requires a lumen ID within the “U” segment of no more than 0.046″ given a prong length of 8 mm and a prong spacing of 16 mm. Therefore, a lumen ID significantly larger than 0.046″ would not be advantageous to maintaining dose volume accuracy for minimum dose volumes of 0.35 mL. Of course, it is understood that the mathematics of this construct would be modified by systems with larger or smaller minimum dose volumes appropriately, or with different prong lengths and/or prong spacing. One skilled in the art can perform the required calculations to determine the ID required to provide a desired volume in the “U” section so that it does not exceed 10% of the dose volume. Furthermore, depending on the required accuracy for the dosing, the internal “U” volume or other volume available for cross-flow may be less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2% or 1% of the dose volume.
In addition to the volumetric dosing accuracy concern, another concern is that the second lumen ID not produce gas flow distortion. However, given that gas flow in a nitric oxide system may use restrictors which are significantly smaller in inner diameter than a NO lumen ID of 0.046 inches, such distortion may not actually occur.
Finally, the inner diameter of the second lumen preferably does not produce undue signal propagation delay from the patient to the device. Such delay is believed to occur as pneumatic tubes behave as first order pneumatic low pass filters and attenuate higher bandwidth signal components. Modification of the inner diameters is known to change the band pass characteristics of the filtering effect. However, as noted earlier, the inner diameter (at the U) may be fixed to a certain maximum ID based on the required dose delivery accuracy of the system. Therefore, in order to minimize the effects of the potentially frequency attenuated pressure signal, two measures can be taken. First the upstream (close to device) diameter of the second lumen may be adjusted to widen (optimize) the band pass characteristics of the cannula. This may ensure that unneeded compressible volume is unavailable upstream of the nose piece restriction (0.046″ ID restriction). This reduces the compressible volume in the cannula and effectively increases the bandpass characteristics of the cannula. The second measure which can be taken is to trigger the initiation of pulse delivery on the device not based on a threshold pressure level (the magnitude of which can which can be delayed by frequency attenuation) but by triggering the device based on a pattern of sloping pressure indicative of patient effort. Such a slope may be reduced in magnitude by the filtering characteristics of the tubing, however, the slope will still be present for algorithmic triggering decisions by the device. However, such a triggering implementation is optional.
Accordingly, in some embodiments, the dual lumen cannula would have an oxygen lumen in the range from 0.05 to 0.12″ ID (such as about 0.080″ ID) which tees at the nosepiece and is in fluid communication with both nares. It would also have a second (nitric oxide) lumen (similarly in fluid communication with both nares) with an internal tubing diameter dictated by volumetric dosing accuracy considerations and the second lumen may have an ID in the range from 0.01 to 0.08″ (such as about 0.046″ ID) with upstream tubing adjusted to optimize the bandpass performance of the system. Finally, device triggering methodologies based not on pressure thresholds, but based on pressure slope trends can also be employed to improve overall timely delivery of dosing to the patient.
Other pneumatic configurations for the nasal cannula may utilize different numbers of lumina. In one or more embodiments, the nasal cannula has three lumina (i.e. a tri-lumen cannula).
Again, all three of the lumina may be integrated into a single cannula.
The tubes of the cannula carry backwards towards the patient and may be affixed to each other so as to produce a clean single element umbilical between the cannula head and the device as shown in
As can be seen from
All of the above may serve to reduce the potential for retrograde flow and/or reduce the volume of retrograde flow and/or reduce the contact or contact duration between NO and other gasses including oxygen in the cannula. This will reduce the dilution of NO and thereby increase the precision of the delivered NO dose.
The ID of the NO lumen may decrease from a maximum ID to a minimum ID. In some embodiments, the ratio of the minimum ID to the maximum ID of the NO lumen may be 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9 or 1:10.
The trigger lumen ID may be comparatively much larger than the NO lumen ID. Trigger pressure drop on inhalation must be transmitted through this cannula lumen with the smallest possible loss of signal magnitude to the NO delivery device which in turn uses this pressure signal to deliver pulsed NO. Again, in some embodiments, the ratio of the ID of the NO lumen to the ID of trigger lumen may be 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25 or 1:30.
The oxygen lumen may also be larger than the NO lumen to minimize oxygen flow resistance and to reduce gas flow speed at the prongs which could serve to interfere with the triggering pressure signal due to gas flow effects such from Bernoulli's principle. As with the trigger lumen, in some embodiments the ratio of the ID of the NO lumen to the ID of the oxygen lumen may be 1:1, 1:1.2, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25 or 1:30.
Another pneumatic configuration is shown in
One potential benefit of the quad-lumen approach is to prevent movement of gas through the tee'd delivery loop of the NO supply line during exhalation. This may reduce NO/oxygen contact. However, unlike the tri-lumen cannula, use of the quad-lumen cannula may require dedicated pneumatic circuitry for each NO lumen.
With any of the pneumatic configurations described herein, there may be other modifications of the cannula to improve NO dosing. In one or more embodiments, provided is a nasal cannula with one or more check valves in the nitric oxide delivery line. This configuration may be combined with one of the multi-lumen configurations described above. The check valves(s) help to prevent retrograde gas movement into the NO supply lumen during inhalation/exhalation. Such a check valve might consist of any low cracking pressure check valve which is placed at some point in the NO delivery path. Such check valves may include, but are not limited to, duckbill valves or umbrella valves. Exemplary duck bill valves are shown in
In one or more embodiments, provided is an NO delivery cannula having a small flapper or umbrella check valve at the head of the cannula allowing pulses of NO to be delivered to the general nose/mouth area during device NO pulsing. An exemplary configuration of a nasal cannula with such a flapper or umbrella valve is shown in
This pneumatic configuration may be combined with any of the other pneumatic configurations described above.
In one or more embodiments, also provided is a nasal cannula incorporating an impermeable or semi-permeable membrane. The membrane may be movable or fixed but can be actively or passively moved when needed, that separates the NO containing gas or material from the O2 containing gas or material until the NO needs to be delivered to the patient. This membrane may reduce one or more of the contact time, surface area and diffusion rate between the NO and O2 containing gases. This may reduce the formation of NO2, which dilutes the intended NO delivery concentration.
In some embodiments of the membrane, a normally-closed valve at the tip of the NO containing cannula prevents air from contacting the NO containing gas inside the cannula until the valve opening is triggered (e.g. by a drop in pressure caused by inhalation by the patient or by the positive pressure caused by the delivery device as it attempts to deliver the NO containing gas to the patient). When the valve opening is triggered, the NO is then delivered to the patient. One embodiment of such a valve is shown in
In one or more embodiments, also provided is a system to expel the gas or other NO containing material that does come in contact with O2 containing gas or material, which may have otherwise formed NO2 in this mixture. The system may subsequently allow another part of the NO containing gas or material that has minimal or no NO2 to be delivered to the patient Again, this NO2 formation could serve to dilute the NO dose before delivery to the patient.
In some embodiments of this system, this system may comprise an electromechanical valve system that actuates to pump out a fixed or adjustable amount of gas mixture that might contain NO2 through a separate orifice than the cannula opening to the patient. The system may then actuate to pump the NO containing gas or material to the patient. One embodiment of such a system is shown as a 3-way valve in
The membrane and/or valve system may be combined with any of the other pneumatic configurations described above.
Manufacturing of Multi-Lumen Nasal Cannulas
As described above, the individual lumen of a multi-lumen cannula may be separately manufactured and then affixed to each other, or the multiple lumina can be extruded through a single die producing a multi-lumen tube.
According to one or more embodiments, the multi-lumen nosepiece of the multi-lumen cannulas described herein may be manufactured by the following molding technique. For example, the cannula may have a triple lumen cannula nosepiece for separate oxygen, nitric oxide and triggering lumina. In one or more embodiments, the design of the nosepiece for the triple lumen cannula involves three lumens, two with inner diameters of approximately 0.080″ (for oxygen and triggering) and one with a smaller inner diameter of approximately 0.045″ (for nitric oxide) as shown in
Accordingly, one approach to manufacture the multi-lumen cannula nosepiece is to mold two halves in urethane, PVC, silicone or other low durometer elastomer with the internals of the large lumen defined by larger injector pins (outer diameter 0.080″) and with small half lumen indents defining the outline of the small lumen. These two halves would then be folded and bonded together, preferably with a bonding technique which does not produce residue or flash such as RF welding, to form a whole nosepiece.
Again, the lumen ID may be adjusted as described in the previous sections. For example, the ID of the oxygen lumen may range from 0.05 to 0.12″, the ID of the trigger lumen may range from 0.05 to 0.12″, and the ID of the NO lumen may range from 0.01 to 0.08″. In some embodiments, the IDs of the oxygen lumen and the trigger lumen may both be in the range from 0.07″ to 0.09″ (such as about 0.08″) and the ID of the NO lumen may be in the range from 0.035 to 0.055″ (such as about 0.045″).
An alternate embodiment shown in
Methods of Treatment
Any of the nasal cannulas described herein may be used in nitric oxide therapy to treat appropriate diseases. For example, the cannulas may be for pulsed NO therapy to treat chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH). For these diseases, the delivery of the appropriate dose amounts and appropriate dose timing may be very important. For COPD, the NO may need to be pulsed early in inspiration, such as the first half of inspiration. If NO is not delivered in the right amount or at the right time, reversal of hypoxic vasoconstriction may occur, which would worsen the patient's condition. Furthermore, the dose amount may be very important for PAH because sudden discontinuation of therapy can lead to serious events such as rebound hypertension. Thus, significant dilution of the NO dose should be minimized for these diseases. Any of the cannula materials, configurations or methods described herein may be used to minimize dilution of the NO dose during NO therapy.
Examples
The retrograde flow for various nasal cannula configurations was tested. Typical nasal cannulas that deliver to both nares result in significant retrograde flow as shown in Test 1 of
Reference throughout this specification to “one embodiment,” “certain embodiments,” “one or more embodiments” or “an embodiment” means that a particular feature, structure, material, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrases such as “in one or more embodiments,” “in certain embodiments,” “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily referring to the same embodiment of the invention. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments.
Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the method and apparatus of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention include modifications and variations that are within the scope of the appended claims and their equivalents.
This application claims, under 35 USC §119(e), the benefit of U.S. Provisional Application No. 61/733,134, filed Dec. 4, 2012 and U.S. Provisional Application No. 61/784,238, filed Mar. 14, 2013 the contents of both of which are hereby incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
759152 | Bennett | May 1904 | A |
1369631 | De Vilbiss | Feb 1921 | A |
1443820 | Hudson | Jan 1923 | A |
1856811 | Inaki | May 1932 | A |
2860634 | Duncan et al. | Nov 1958 | A |
2931358 | Sheridan | Apr 1960 | A |
3260258 | Berman | Jul 1966 | A |
3513844 | Smith | May 1970 | A |
3682171 | Dali et al. | Aug 1972 | A |
3867946 | Huddy | Feb 1975 | A |
3877436 | Havstad | Apr 1975 | A |
3915173 | Brekke | Oct 1975 | A |
3951175 | Eberhart | Apr 1976 | A |
3972321 | Proctor | Aug 1976 | A |
4015366 | Hall, III | Apr 1977 | A |
4015598 | Brown | Apr 1977 | A |
4054133 | Myers | Oct 1977 | A |
4151843 | Brekke et al. | May 1979 | A |
4265235 | Fukunaga | May 1981 | A |
4280493 | Council | Jul 1981 | A |
4291691 | Cabal et al. | Sep 1981 | A |
4300550 | Gandi et al. | Nov 1981 | A |
4320754 | Watson et al. | Mar 1982 | A |
4333451 | Paluch | Jun 1982 | A |
RE31023 | Hall, III | Sep 1982 | E |
4363323 | Geiss | Dec 1982 | A |
4403611 | Babbitt et al. | Sep 1983 | A |
4462397 | Suzuki | Jul 1984 | A |
4465067 | Koch et al. | Aug 1984 | A |
4485822 | O'Connor et al. | Dec 1984 | A |
4517404 | Hughes et al. | May 1985 | A |
4521038 | Cerny | Jun 1985 | A |
4535767 | Tiep et al. | Aug 1985 | A |
4559941 | Timmons et al. | Dec 1985 | A |
4584997 | Delong | Apr 1986 | A |
4602644 | DiBenedetto et al. | Jul 1986 | A |
4634425 | Meer | Jan 1987 | A |
4648398 | Agdanowski et al. | Mar 1987 | A |
4660555 | Payton | Apr 1987 | A |
4699139 | Marshall et al. | Oct 1987 | A |
4778448 | Meer | Oct 1988 | A |
4790832 | Lopez | Dec 1988 | A |
4796615 | Bullock et al. | Jan 1989 | A |
4801093 | Brunet et al. | Jan 1989 | A |
4821715 | Downing | Apr 1989 | A |
4826510 | McCombs | May 1989 | A |
4829998 | Jackson | May 1989 | A |
4838257 | Hatch | Jun 1989 | A |
4893620 | Wadwha | Jan 1990 | A |
4949716 | Chenoweth | Aug 1990 | A |
4957107 | Sipin | Sep 1990 | A |
4989599 | Carter | Feb 1991 | A |
4996983 | AmRhein | Mar 1991 | A |
5011474 | Brennan | Apr 1991 | A |
5018519 | Brown | May 1991 | A |
5025805 | Nutter | Jun 1991 | A |
5027809 | Robinson | Jul 1991 | A |
5027812 | Shapiro et al. | Jul 1991 | A |
5046491 | Derrick | Sep 1991 | A |
5088486 | Jinotti | Feb 1992 | A |
5099836 | Rowland et al. | Mar 1992 | A |
5105807 | Kahn et al. | Apr 1992 | A |
5109839 | Blasdell et al. | May 1992 | A |
5117818 | Palfy | Jun 1992 | A |
5121746 | Sikora | Jun 1992 | A |
5140983 | Jinotti | Aug 1992 | A |
5222486 | Vaughn | Jun 1993 | A |
5243971 | Sullivan | Sep 1993 | A |
5269296 | Landis | Dec 1993 | A |
5291897 | Gastrin et al. | Mar 1994 | A |
5311862 | Blasdell et al. | May 1994 | A |
5331954 | Rex et al. | Jul 1994 | A |
5357948 | Eilentripp | Oct 1994 | A |
5400776 | Bartholomew | Mar 1995 | A |
5404873 | Leagre et al. | Apr 1995 | A |
5419317 | Blasdell et al. | May 1995 | A |
5429127 | Kolobow | Jul 1995 | A |
5437267 | Weinstein et al. | Aug 1995 | A |
5526806 | Sansoni | Jun 1996 | A |
5538000 | Rudolph | Jul 1996 | A |
5540221 | Kaigler et al. | Jul 1996 | A |
5599304 | Shaari | Feb 1997 | A |
5601077 | Imbert | Feb 1997 | A |
5603315 | Sasso, Jr. | Feb 1997 | A |
5605149 | Warters | Feb 1997 | A |
5626130 | Vincent et al. | May 1997 | A |
5632268 | Ellis et al. | May 1997 | A |
5640951 | Huddart et al. | Jun 1997 | A |
5664567 | Linder | Sep 1997 | A |
5676137 | Byrd | Oct 1997 | A |
5682881 | Winthrop et al. | Nov 1997 | A |
5683361 | Elk et al. | Nov 1997 | A |
5692498 | Lurie et al. | Dec 1997 | A |
5743258 | Sato et al. | Apr 1998 | A |
5752506 | Richardson | May 1998 | A |
5755225 | Hutson | May 1998 | A |
5787879 | Gibson | Aug 1998 | A |
5788665 | Sekins | Aug 1998 | A |
5803078 | Brauner | Sep 1998 | A |
5845633 | Psaros | Dec 1998 | A |
5862802 | Bird | Jan 1999 | A |
5873359 | Zapol et al. | Feb 1999 | A |
5893361 | Hughes | Apr 1999 | A |
5901705 | Leagre | May 1999 | A |
5928190 | Davis | Jul 1999 | A |
5947119 | Reznick | Sep 1999 | A |
5954050 | Christopher | Sep 1999 | A |
5989217 | Ohki | Nov 1999 | A |
6012455 | Goldstein | Jan 2000 | A |
6058932 | Hughes | May 2000 | A |
6067984 | Piper | May 2000 | A |
6119693 | Kwok et al. | Sep 2000 | A |
6142147 | Head et al. | Nov 2000 | A |
6152132 | Psaros | Nov 2000 | A |
6155252 | Warters | Dec 2000 | A |
6228070 | Mezzoli | May 2001 | B1 |
6247470 | Ketchedjian | Jun 2001 | B1 |
6267114 | Ueno | Jul 2001 | B1 |
6270512 | Rittmann | Aug 2001 | B1 |
6279576 | Lambert | Aug 2001 | B1 |
6283123 | Van Meter et al. | Sep 2001 | B1 |
6318366 | Davenport | Nov 2001 | B1 |
6378520 | Davenport | Apr 2002 | B1 |
6394093 | Lethi | May 2002 | B1 |
6394142 | Woelfel et al. | May 2002 | B1 |
6412801 | Izuchukwu et al. | Jul 2002 | B1 |
6422240 | Levitsky et al. | Jul 2002 | B1 |
6425396 | Adriance et al. | Jul 2002 | B1 |
6431218 | Woelfel et al. | Aug 2002 | B1 |
6439230 | Gunaratnam et al. | Aug 2002 | B1 |
6439231 | Fukunaga et al. | Aug 2002 | B1 |
6446629 | Takaki et al. | Sep 2002 | B1 |
6463931 | Kwok et al. | Oct 2002 | B1 |
6505622 | Py | Jan 2003 | B2 |
6505624 | Campbell, Sr. | Jan 2003 | B1 |
6520931 | Suh | Feb 2003 | B2 |
6536436 | McGlothen | Mar 2003 | B1 |
6540718 | Wennek | Apr 2003 | B1 |
6543449 | Woodring et al. | Apr 2003 | B1 |
6561188 | Ellis | May 2003 | B1 |
6561193 | Noble | May 2003 | B1 |
6564799 | Fukunaga et al. | May 2003 | B2 |
6571794 | Hansen | Jun 2003 | B1 |
6581599 | Stenzler | Jun 2003 | B1 |
6584973 | Biondi et al. | Jul 2003 | B1 |
6604523 | Lurie | Aug 2003 | B2 |
6631717 | Rich | Oct 2003 | B1 |
6655385 | Curti et al. | Dec 2003 | B1 |
6659100 | O'Rourke | Dec 2003 | B2 |
6668828 | Figley et al. | Dec 2003 | B1 |
6679250 | Walker et al. | Jan 2004 | B2 |
6681764 | Honkonen et al. | Jan 2004 | B1 |
6684882 | Morine | Feb 2004 | B1 |
6698423 | Honkonen et al. | Mar 2004 | B1 |
6772761 | Rucker, Jr. | Aug 2004 | B1 |
6776162 | Wood | Aug 2004 | B2 |
6776163 | Dougill et al. | Aug 2004 | B2 |
6789543 | Cannon | Sep 2004 | B2 |
6799570 | Fisher et al. | Oct 2004 | B2 |
6799575 | Carter | Oct 2004 | B1 |
6805126 | Dutkiewicz | Oct 2004 | B2 |
6828577 | Zens | Dec 2004 | B2 |
6849049 | Starr et al. | Feb 2005 | B2 |
6863069 | Wood | Mar 2005 | B2 |
6866041 | Hardy, Jr. et al. | Mar 2005 | B2 |
6874500 | Fukunaga et al. | Apr 2005 | B2 |
6880557 | Downey | Apr 2005 | B2 |
6886561 | Bayron et al. | May 2005 | B2 |
6889688 | Wright | May 2005 | B1 |
6899102 | McGlothen | May 2005 | B1 |
6901927 | Deem et al. | Jun 2005 | B2 |
6915965 | Siebert | Jul 2005 | B2 |
6938619 | Hickle | Sep 2005 | B1 |
6948493 | Dunlop | Sep 2005 | B2 |
6983749 | Kumar | Jan 2006 | B2 |
6994089 | Wood | Feb 2006 | B2 |
6997918 | Soltesz et al. | Feb 2006 | B2 |
7000610 | Bennarsten et al. | Feb 2006 | B2 |
7007691 | Daugherty et al. | Mar 2006 | B2 |
7007694 | Aylsworth et al. | Mar 2006 | B2 |
7011094 | Rapacki et al. | Mar 2006 | B2 |
7013899 | Alfery et al. | Mar 2006 | B2 |
7017573 | Rasor et al. | Mar 2006 | B1 |
7032589 | Kerechanin, II et al. | Apr 2006 | B2 |
7036506 | McAuliffe et al. | May 2006 | B2 |
7051736 | Banner et al. | May 2006 | B2 |
7059328 | Wood | Jun 2006 | B2 |
7066174 | Smith et al. | Jun 2006 | B1 |
7096864 | Mayer et al. | Aug 2006 | B1 |
7100606 | Fisher et al. | Sep 2006 | B2 |
7114497 | Aylsworth et al. | Oct 2006 | B2 |
7121276 | Jagger et al. | Oct 2006 | B2 |
7140370 | Tresnak et al. | Nov 2006 | B2 |
7146976 | McKown | Dec 2006 | B2 |
7152604 | Hickle | Dec 2006 | B2 |
7165549 | Philipps et al. | Jan 2007 | B2 |
7178521 | Burrow et al. | Feb 2007 | B2 |
7178524 | Noble | Feb 2007 | B2 |
7195018 | Goldstein | Mar 2007 | B1 |
7204247 | Rogerson | Apr 2007 | B1 |
7204249 | Richey, II et al. | Apr 2007 | B1 |
7204251 | Lurie | Apr 2007 | B2 |
7210481 | Lovell et al. | May 2007 | B1 |
7252088 | Nieves-Ramirez | Aug 2007 | B1 |
7261105 | Fukunaga et al. | Aug 2007 | B2 |
7273050 | Wei | Sep 2007 | B2 |
7275541 | Fukunaga et al. | Oct 2007 | B2 |
7278420 | Ganesh et al. | Oct 2007 | B2 |
7290543 | Stradella | Nov 2007 | B2 |
7318437 | Gunaratnam et al. | Jan 2008 | B2 |
7320447 | Lynch | Jan 2008 | B1 |
7328703 | Tiep | Feb 2008 | B1 |
7334578 | Biondi et al. | Feb 2008 | B2 |
7343916 | Biondo et al. | Mar 2008 | B2 |
7354467 | Chen et al. | Apr 2008 | B2 |
7383839 | Porat et al. | Jun 2008 | B2 |
7406966 | Wondka | Aug 2008 | B2 |
7418965 | Fukunaga et al. | Sep 2008 | B2 |
7428902 | Du et al. | Sep 2008 | B2 |
7434578 | Dillard | Oct 2008 | B2 |
7445602 | Yamamori et al. | Nov 2008 | B2 |
7461649 | Gamard et al. | Dec 2008 | B2 |
7461656 | Gunaratnam et al. | Dec 2008 | B2 |
7478634 | Jam | Jan 2009 | B2 |
7481219 | Lewis et al. | Jan 2009 | B2 |
7481222 | Reissmann | Jan 2009 | B2 |
7481223 | Batistelli | Jan 2009 | B1 |
7503325 | Fuhrman et al. | Mar 2009 | B2 |
7506649 | Doshi et al. | Mar 2009 | B2 |
7523752 | Montgomery et al. | Apr 2009 | B2 |
7527053 | DeVries et al. | May 2009 | B2 |
7533670 | Freitag et al. | May 2009 | B1 |
7552728 | Bonney et al. | Jun 2009 | B2 |
7578294 | Pierro et al. | Aug 2009 | B2 |
7600511 | Power et al. | Oct 2009 | B2 |
7617824 | Doyle | Nov 2009 | B2 |
7631668 | Rantalainen | Dec 2009 | B2 |
7655063 | Wang et al. | Feb 2010 | B2 |
7658189 | Davidson et al. | Feb 2010 | B2 |
7708016 | Zaiser et al. | May 2010 | B2 |
7708017 | Davidson et al. | May 2010 | B2 |
7717109 | Fukunaga et al. | May 2010 | B2 |
7717116 | Mijers | May 2010 | B2 |
7727194 | Nalagatla et al. | Jun 2010 | B2 |
7735490 | Rinaldi | Jun 2010 | B2 |
7735491 | Doshi et al. | Jun 2010 | B2 |
7740014 | Djupesland | Jun 2010 | B2 |
7743767 | Ging et al. | Jun 2010 | B2 |
7762253 | Acker et al. | Jul 2010 | B2 |
7775210 | Schobel (nee Bauer) et al. | Aug 2010 | B2 |
7779841 | Dunsmore et al. | Aug 2010 | B2 |
7798148 | Doshi et al. | Sep 2010 | B2 |
7806120 | Loomas et al. | Oct 2010 | B2 |
7832400 | Curti et al. | Nov 2010 | B2 |
7837651 | Bishop et al. | Nov 2010 | B2 |
7854228 | Wilson et al. | Dec 2010 | B2 |
7856979 | Doshi et al. | Dec 2010 | B2 |
7856981 | McAuley et al. | Dec 2010 | B2 |
7866320 | Nichols | Jan 2011 | B2 |
7870857 | Chuper et al. | Jan 2011 | B2 |
7874291 | Ging et al. | Jan 2011 | B2 |
7874293 | Gunaratnam et al. | Jan 2011 | B2 |
7900635 | Gunaratnam et al. | Mar 2011 | B2 |
7905232 | Olsen et al. | Mar 2011 | B2 |
7918224 | Dolezal et al. | Apr 2011 | B2 |
7918225 | Dolezal et al. | Apr 2011 | B2 |
7918227 | Phythyon | Apr 2011 | B1 |
7926484 | Dhuper et al. | Apr 2011 | B2 |
7942148 | Davidson et al. | May 2011 | B2 |
7942150 | Guney et al. | May 2011 | B2 |
7946288 | Flynn et al. | May 2011 | B2 |
7970631 | Bruggeman et al. | Jun 2011 | B2 |
7985254 | Tolkowsky | Jul 2011 | B2 |
7987847 | Wickham et al. | Aug 2011 | B2 |
7987852 | Doshi et al. | Aug 2011 | B2 |
7992561 | Baker, Jr. et al. | Aug 2011 | B2 |
7997266 | Frazier et al. | Aug 2011 | B2 |
7997267 | Ging et al. | Aug 2011 | B2 |
7997271 | Hickle et al. | Aug 2011 | B2 |
8015974 | Christopher et al. | Sep 2011 | B2 |
8020556 | Hayek | Sep 2011 | B2 |
8020558 | Christopher et al. | Sep 2011 | B2 |
8025054 | Dunsmore et al. | Sep 2011 | B2 |
8025055 | Grady | Sep 2011 | B1 |
8025059 | Reissmann | Sep 2011 | B2 |
8025635 | Eaton et al. | Sep 2011 | B2 |
8028697 | Grychowski et al. | Oct 2011 | B2 |
8042536 | Howey | Oct 2011 | B1 |
8042542 | Ging et al. | Oct 2011 | B2 |
8042546 | Gunaratnam et al. | Oct 2011 | B2 |
8061357 | Pierce et al. | Nov 2011 | B2 |
8080000 | Makower et al. | Dec 2011 | B2 |
8090433 | Makower et al. | Jan 2012 | B2 |
8113198 | Teetzel et al. | Feb 2012 | B2 |
8136527 | Wondka | Mar 2012 | B2 |
8146591 | Niklewski et al. | Apr 2012 | B2 |
8146592 | Voege et al. | Apr 2012 | B2 |
8151790 | Lurie et al. | Apr 2012 | B2 |
8161971 | Jaffe et al. | Apr 2012 | B2 |
RE43398 | Honkonen et al. | May 2012 | E |
8171935 | Cortez, Jr. et al. | May 2012 | B2 |
8177805 | Alferness | May 2012 | B2 |
8181646 | Dhuper et al. | May 2012 | B2 |
8186352 | Gunaratnam et al. | May 2012 | B2 |
8191551 | Skovgard | Jun 2012 | B2 |
8196579 | Richards et al. | Jun 2012 | B2 |
8196582 | Ogilvie | Jun 2012 | B2 |
8215301 | Richards et al. | Jul 2012 | B2 |
8220463 | White et al. | Jul 2012 | B2 |
8225796 | Davenport et al. | Jul 2012 | B2 |
8230859 | Voege et al. | Jul 2012 | B1 |
8245710 | Makinson et al. | Aug 2012 | B2 |
8267083 | Goldstein et al. | Sep 2012 | B1 |
8267087 | Wruck et al. | Sep 2012 | B2 |
8272378 | Tutsch et al. | Sep 2012 | B2 |
8281557 | Doshi et al. | Oct 2012 | B2 |
8286636 | Gunaratnam et al. | Oct 2012 | B2 |
8297285 | Henry et al. | Oct 2012 | B2 |
8302603 | Weber | Nov 2012 | B1 |
8302606 | Doshi et al. | Nov 2012 | B2 |
8302607 | Pierce et al. | Nov 2012 | B2 |
8307829 | Brewer et al. | Nov 2012 | B2 |
8312881 | Gunaratnam et al. | Nov 2012 | B2 |
8312883 | Gunaratnam et al. | Nov 2012 | B2 |
8316851 | Wruck et al. | Nov 2012 | B2 |
8333194 | Lewis et al. | Dec 2012 | B2 |
8333199 | Landis et al. | Dec 2012 | B2 |
8333200 | Tero | Dec 2012 | B2 |
8336545 | Fink et al. | Dec 2012 | B2 |
8337454 | Eaton | Dec 2012 | B2 |
RE43886 | Mijers | Jan 2013 | E |
8342182 | Nair et al. | Jan 2013 | B2 |
8347881 | Tanaka et al. | Jan 2013 | B2 |
8347883 | Bird | Jan 2013 | B2 |
8348854 | Girshin | Jan 2013 | B2 |
8356595 | Schaeffer, Jr. et al. | Jan 2013 | B2 |
8371297 | Carey et al. | Feb 2013 | B2 |
8371302 | Ging et al. | Feb 2013 | B2 |
8371303 | Schaner et al. | Feb 2013 | B2 |
8375952 | Miller et al. | Feb 2013 | B2 |
8387616 | Ging et al. | Mar 2013 | B2 |
8402970 | Levi et al. | Mar 2013 | B2 |
8408204 | Lurie | Apr 2013 | B2 |
8408206 | Montgomery et al. | Apr 2013 | B2 |
8409168 | Wondka et al. | Apr 2013 | B2 |
8424529 | Efrati et al. | Apr 2013 | B2 |
8424530 | Gunaratnam et al. | Apr 2013 | B2 |
8439034 | Decker et al. | May 2013 | B2 |
8443802 | Schaeffer, Jr. et al. | May 2013 | B2 |
8448639 | Richards et al. | May 2013 | B2 |
8469025 | Mayer et al. | Jun 2013 | B2 |
8469027 | Choncholas | Jun 2013 | B2 |
8474449 | Tanaka | Jul 2013 | B2 |
8475369 | Boatner et al. | Jul 2013 | B2 |
8486043 | Iyer et al. | Jul 2013 | B2 |
8522782 | Lewis et al. | Sep 2013 | B2 |
8534278 | Colman et al. | Sep 2013 | B2 |
8534286 | Pierro et al. | Sep 2013 | B2 |
8555877 | Djupesland | Oct 2013 | B2 |
8555887 | Lisogurski | Oct 2013 | B2 |
8561607 | Cortez, Jr. et al. | Oct 2013 | B2 |
8770199 | Flanagan et al. | Jul 2014 | B2 |
9032959 | Flanagan et al. | May 2015 | B2 |
20010037808 | Deem et al. | Nov 2001 | A1 |
20010047804 | Fukunaga | Dec 2001 | A1 |
20020017302 | Fukunaga et al. | Feb 2002 | A1 |
20020046755 | De Voss | Apr 2002 | A1 |
20020054422 | Smith et al. | May 2002 | A1 |
20020055685 | Levitsky et al. | May 2002 | A1 |
20020069878 | Lurie et al. | Jun 2002 | A1 |
20020092527 | Wood | Jul 2002 | A1 |
20020108610 | Christopher | Aug 2002 | A1 |
20020112730 | Dutkiewicz | Aug 2002 | A1 |
20020121278 | Hete et al. | Sep 2002 | A1 |
20020148464 | Hoenig | Oct 2002 | A1 |
20020185126 | Krebs | Dec 2002 | A1 |
20030075176 | Fukunaga et al. | Apr 2003 | A1 |
20030079750 | Berthon-Jones | May 2003 | A1 |
20030116163 | Wood | Jun 2003 | A1 |
20030131844 | Kumar et al. | Jul 2003 | A1 |
20030131848 | Stenzler | Jul 2003 | A1 |
20030154979 | Berthon-Jones | Aug 2003 | A1 |
20030168058 | Walker et al. | Sep 2003 | A1 |
20030168067 | Dougill et al. | Sep 2003 | A1 |
20030172929 | Muellner | Sep 2003 | A1 |
20030172936 | Wilkie et al. | Sep 2003 | A1 |
20030183231 | Pedulla et al. | Oct 2003 | A1 |
20030183232 | Fukunaga et al. | Oct 2003 | A1 |
20030209246 | Schroeder et al. | Nov 2003 | A1 |
20030213493 | Saad | Nov 2003 | A1 |
20040000306 | Stradella | Jan 2004 | A1 |
20040000314 | Angel | Jan 2004 | A1 |
20040069304 | Jam | Apr 2004 | A1 |
20040069309 | Kirn | Apr 2004 | A1 |
20040103899 | Noble | Jun 2004 | A1 |
20040112378 | Djupesland | Jun 2004 | A1 |
20040112379 | Djupesland | Jun 2004 | A1 |
20040112380 | Djupesland | Jun 2004 | A1 |
20040129270 | Fishman | Jul 2004 | A1 |
20040134498 | Strickland et al. | Jul 2004 | A1 |
20040139973 | Wright | Jul 2004 | A1 |
20040149289 | Djupesland | Aug 2004 | A1 |
20040163647 | Figley et al. | Aug 2004 | A1 |
20040173212 | Berthon-Jones | Sep 2004 | A1 |
20040182397 | Wood | Sep 2004 | A1 |
20040194781 | Fukunaga et al. | Oct 2004 | A1 |
20040206354 | Fisher et al. | Oct 2004 | A1 |
20040216740 | Remmers et al. | Nov 2004 | A1 |
20040221845 | Pranger et al. | Nov 2004 | A1 |
20040221846 | Curti et al. | Nov 2004 | A1 |
20040226566 | Gunaratnam et al. | Nov 2004 | A1 |
20040231675 | Lyons | Nov 2004 | A1 |
20040244802 | Tanaka | Dec 2004 | A1 |
20040244804 | Olsen et al. | Dec 2004 | A1 |
20050005936 | Wondka | Jan 2005 | A1 |
20050011524 | Thomlinson et al. | Jan 2005 | A1 |
20050022828 | Fukunaga et al. | Feb 2005 | A1 |
20050028816 | Fishman et al. | Feb 2005 | A1 |
20050028823 | Wood | Feb 2005 | A1 |
20050034726 | Pittaway et al. | Feb 2005 | A1 |
20050039747 | Fukunaga et al. | Feb 2005 | A1 |
20050051163 | Deem et al. | Mar 2005 | A1 |
20050051176 | Riggins | Mar 2005 | A1 |
20050066973 | Michaels | Mar 2005 | A1 |
20050072430 | Djupesland | Apr 2005 | A1 |
20050103340 | Wondka | May 2005 | A1 |
20050103346 | Noble | May 2005 | A1 |
20050103347 | Curti et al. | May 2005 | A1 |
20050121033 | Starr et al. | Jun 2005 | A1 |
20050137715 | Phan et al. | Jun 2005 | A1 |
20050150501 | Opitz | Jul 2005 | A1 |
20050161049 | Wright | Jul 2005 | A1 |
20050166927 | McAuley et al. | Aug 2005 | A1 |
20050188990 | Fukunaga et al. | Sep 2005 | A1 |
20050199237 | Lurie | Sep 2005 | A1 |
20050205098 | Lampotang et al. | Sep 2005 | A1 |
20050217671 | Fisher et al. | Oct 2005 | A1 |
20050236000 | Wood | Oct 2005 | A1 |
20050252515 | Wood | Nov 2005 | A1 |
20050257794 | Aylsworth et al. | Nov 2005 | A1 |
20060011198 | Matarasso | Jan 2006 | A1 |
20060042631 | Martin et al. | Mar 2006 | A1 |
20060042632 | Bishop et al. | Mar 2006 | A1 |
20060042634 | Nalagatla et al. | Mar 2006 | A1 |
20060042636 | Nalagatla et al. | Mar 2006 | A1 |
20060042637 | Martin et al. | Mar 2006 | A1 |
20060042638 | Niklewski et al. | Mar 2006 | A1 |
20060060204 | Fuentes | Mar 2006 | A1 |
20060081257 | Krogh et al. | Apr 2006 | A1 |
20060107957 | Djupesland | May 2006 | A1 |
20060130840 | Porat et al. | Jun 2006 | A1 |
20060144401 | Boelt | Jul 2006 | A1 |
20060150979 | Doshi et al. | Jul 2006 | A1 |
20060150982 | Wood | Jul 2006 | A1 |
20060169281 | Aylsworth et al. | Aug 2006 | A1 |
20060174886 | Curti et al. | Aug 2006 | A1 |
20060174888 | Aylsworth et al. | Aug 2006 | A1 |
20060196502 | Pilcher et al. | Sep 2006 | A1 |
20060201512 | Garrett et al. | Sep 2006 | A1 |
20060207596 | Lane | Sep 2006 | A1 |
20060243278 | Hamilton et al. | Nov 2006 | A1 |
20060272645 | Ging et al. | Dec 2006 | A1 |
20070062538 | Foggia et al. | Mar 2007 | A1 |
20070062539 | Gunaratnam et al. | Mar 2007 | A1 |
20070068521 | Wang et al. | Mar 2007 | A1 |
20070107728 | Ricciardelli et al. | May 2007 | A1 |
20070107737 | Landis et al. | May 2007 | A1 |
20070113847 | Acker et al. | May 2007 | A1 |
20070113848 | Acker et al. | May 2007 | A1 |
20070113850 | Acker et al. | May 2007 | A1 |
20070113856 | Acker et al. | May 2007 | A1 |
20070119451 | Wang et al. | May 2007 | A1 |
20070137644 | Dhuper et al. | Jun 2007 | A1 |
20070163588 | Hebrank et al. | Jul 2007 | A1 |
20070175473 | Lewis et al. | Aug 2007 | A1 |
20070186928 | Be'eri | Aug 2007 | A1 |
20070186930 | Davidson et al. | Aug 2007 | A1 |
20070193580 | Feldhahn et al. | Aug 2007 | A1 |
20070199566 | Be'eri | Aug 2007 | A1 |
20070199568 | Diekens et al. | Aug 2007 | A1 |
20070233012 | Lerrick et al. | Oct 2007 | A1 |
20070256690 | Faram | Nov 2007 | A1 |
20070267025 | Lyons et al. | Nov 2007 | A1 |
20070277823 | Al-Ali et al. | Dec 2007 | A1 |
20070277832 | Doshi et al. | Dec 2007 | A1 |
20070283957 | Schobel (nee Bauer) et al. | Dec 2007 | A1 |
20080041373 | Doshi et al. | Feb 2008 | A1 |
20080041393 | Bracken | Feb 2008 | A1 |
20080051674 | Davenport et al. | Feb 2008 | A1 |
20080053458 | De Silva et al. | Mar 2008 | A1 |
20080060649 | Veliss et al. | Mar 2008 | A1 |
20080078388 | Vandine | Apr 2008 | A1 |
20080078393 | Acker et al. | Apr 2008 | A1 |
20080092891 | Cewers | Apr 2008 | A1 |
20080092906 | Gunaratnam et al. | Apr 2008 | A1 |
20080110451 | Dunsmore et al. | May 2008 | A1 |
20080110455 | Dunsmore et al. | May 2008 | A1 |
20080115787 | Ingenito | May 2008 | A1 |
20080121230 | Cortez et al. | May 2008 | A1 |
20080142003 | Depel | Jun 2008 | A1 |
20080142012 | Farnsworth et al. | Jun 2008 | A1 |
20080142018 | Doshi et al. | Jun 2008 | A1 |
20080142019 | Lewis et al. | Jun 2008 | A1 |
20080167603 | Stenzler et al. | Jul 2008 | A1 |
20080178879 | Roberts et al. | Jul 2008 | A1 |
20080190436 | Jaffe et al. | Aug 2008 | A1 |
20080196728 | Ho | Aug 2008 | A1 |
20080216838 | Wondka | Sep 2008 | A1 |
20080221470 | Sather | Sep 2008 | A1 |
20080251079 | Richey | Oct 2008 | A1 |
20080276937 | Davidson et al. | Nov 2008 | A1 |
20080276941 | Doty et al. | Nov 2008 | A1 |
20090025723 | Schobel et al. | Jan 2009 | A1 |
20090044808 | Guney et al. | Feb 2009 | A1 |
20090056717 | Richards et al. | Mar 2009 | A1 |
20090065001 | Fishman | Mar 2009 | A1 |
20090071481 | Fishman | Mar 2009 | A1 |
20090101147 | Landis et al. | Apr 2009 | A1 |
20090133697 | Kwok et al. | May 2009 | A1 |
20090145441 | Doshi et al. | Jun 2009 | A1 |
20090188493 | Doshi et al. | Jul 2009 | A1 |
20090194109 | Doshi et al. | Aug 2009 | A1 |
20090197240 | Fishman et al. | Aug 2009 | A1 |
20090205650 | Tanaka et al. | Aug 2009 | A1 |
20090217929 | Kwok et al. | Sep 2009 | A1 |
20090241965 | Sather et al. | Oct 2009 | A1 |
20090248057 | Kotler | Oct 2009 | A1 |
20090250066 | Daly | Oct 2009 | A1 |
20090260625 | Wondka | Oct 2009 | A1 |
20090266365 | Oberle | Oct 2009 | A1 |
20090306529 | Curti et al. | Dec 2009 | A1 |
20090308398 | Ferdinand et al. | Dec 2009 | A1 |
20100000534 | Kooij et al. | Jan 2010 | A1 |
20100043801 | Halling et al. | Feb 2010 | A1 |
20100065053 | Haveri | Mar 2010 | A1 |
20100069770 | Girshin et al. | Mar 2010 | A1 |
20100069820 | Zotz | Mar 2010 | A1 |
20100070050 | Mathis et al. | Mar 2010 | A1 |
20100071693 | Allum et al. | Mar 2010 | A1 |
20100168511 | Muni et al. | Jul 2010 | A1 |
20100192957 | Hobson et al. | Aug 2010 | A1 |
20100212663 | Vedrine et al. | Aug 2010 | A1 |
20100229865 | Boussignac | Sep 2010 | A1 |
20100252042 | Kapust et al. | Oct 2010 | A1 |
20100326441 | Zucker et al. | Dec 2010 | A1 |
20100326447 | Loomas et al. | Dec 2010 | A1 |
20110005528 | Doshi et al. | Jan 2011 | A1 |
20110005530 | Doshi et al. | Jan 2011 | A1 |
20110009763 | Levitsky et al. | Jan 2011 | A1 |
20110011397 | Ziv et al. | Jan 2011 | A1 |
20110011400 | Gentner et al. | Jan 2011 | A1 |
20110017207 | Hendricksen et al. | Jan 2011 | A1 |
20110023891 | Blach et al. | Feb 2011 | A1 |
20110030685 | Wilkinson et al. | Feb 2011 | A1 |
20110040158 | Katz et al. | Feb 2011 | A1 |
20110041855 | Gunaratnam et al. | Feb 2011 | A1 |
20110067704 | Kooij et al. | Mar 2011 | A1 |
20110067708 | Doshi et al. | Mar 2011 | A1 |
20110073110 | Kenyon et al. | Mar 2011 | A1 |
20110073116 | Genger et al. | Mar 2011 | A1 |
20110094518 | Cipollone et al. | Apr 2011 | A1 |
20110100369 | Zhang et al. | May 2011 | A1 |
20110108041 | Sather et al. | May 2011 | A1 |
20110114098 | McAuley et al. | May 2011 | A1 |
20110125052 | Davenport et al. | May 2011 | A1 |
20110146674 | Roschak | Jun 2011 | A1 |
20110209709 | Davidson et al. | Sep 2011 | A1 |
20110245579 | Bruggeman et al. | Oct 2011 | A1 |
20110271962 | White et al. | Nov 2011 | A1 |
20110290256 | Sather et al. | Dec 2011 | A1 |
20120080037 | Guyuron et al. | Apr 2012 | A1 |
20120111332 | Gusky et al. | May 2012 | A1 |
20120118286 | Barodka | May 2012 | A1 |
20120125332 | Niland et al. | May 2012 | A1 |
20120157794 | Goodwin et al. | Jun 2012 | A1 |
20120167894 | O'Leary | Jul 2012 | A1 |
20120192869 | Hayek | Aug 2012 | A1 |
20120192870 | Dugan et al. | Aug 2012 | A1 |
20120209096 | Jaffe et al. | Aug 2012 | A1 |
20120247480 | Varga | Oct 2012 | A1 |
20120285463 | Dillingham et al. | Nov 2012 | A1 |
20120285470 | Sather et al. | Nov 2012 | A9 |
20120325205 | Allum et al. | Dec 2012 | A1 |
20120325206 | Allum et al. | Dec 2012 | A1 |
20120325218 | Brambilla et al. | Dec 2012 | A1 |
20130008447 | Gunaratnam et al. | Jan 2013 | A1 |
20130014754 | Guerra et al. | Jan 2013 | A1 |
20130019864 | Wondka | Jan 2013 | A1 |
20130092159 | Ulrichskotter et al. | Apr 2013 | A1 |
20130092165 | Wondka | Apr 2013 | A1 |
20130092173 | Alexander et al. | Apr 2013 | A1 |
20130104888 | Landis et al. | May 2013 | A1 |
20130104901 | Landis et al. | May 2013 | A1 |
20130158475 | Xia et al. | Jun 2013 | A1 |
20130184602 | Brambilla | Jul 2013 | A1 |
20130190643 | Brambilla | Jul 2013 | A1 |
20130211275 | Curti | Aug 2013 | A1 |
20130263854 | Taylor et al. | Oct 2013 | A1 |
20130312752 | Kapust et al. | Nov 2013 | A2 |
20130327334 | Pierro et al. | Dec 2013 | A1 |
Number | Date | Country |
---|---|---|
8909565 | Oct 1989 | WO |
WO-2012006415 | Jan 2012 | WO |
WO-2012106373 | Aug 2012 | WO |
Entry |
---|
Non-Final Office Action in U.S. Appl. No. 14/096,629, dated Apr. 1, 2014, 12 pages. |
PCT International Search Report and Written Opinion in PCT/US2013/073082, dated Apr. 3, 2014, 17 pages. |
PCT International Search Report and Written Opinion in PCT/US2013/073142, dated Apr. 3, 2014, 17 pages. |
Non-Final Office Action in U.S. Appl. No. 14/096,910, dated Apr. 25, 2014, 45 pages. |
Final Office Action in U.S. Appl. No. 14/096,910, dated Dec. 19, 2014, 19 pages. |
Non-Final Office Action in U.S. Appl. No. 14/312,003 dated May 11, 2016, 32 pages. |
Extended European Search Report in Appln. No. EP 16204677.5 dated Feb. 28, 2017, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20140166009 A1 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
61733134 | Dec 2012 | US | |
61784238 | Mar 2013 | US |